BioAegis Therapeutics Announces FDA Clearance of IND for its ‘Inflammation Regulator Protein,’ Gelsolin, for the Treatment of ARDS
26 janv. 2023 14h05 HE
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma...
BioAegis Leverages Gelsolin’s Broad Therapeutic Applicability by Expanding into Multiple Inflammatory Diseases
06 janv. 2023 14h50 HE
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Jan. 06, 2023 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma...
Enlivex Receives Authorizations from French and Belgian Regulatory Agencies To Expand Its Phase II Sepsis Clinical Trial Into France and Belgium
04 janv. 2023 08h00 HE
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
Global AI and Trust in Healthcare Research Report 2022: Validation of Models, Explainability and Transparency, & Data Ethics and AI
23 nov. 2022 06h38 HE
|
Research and Markets
Dublin, Nov. 23, 2022 (GLOBE NEWSWIRE) -- The "2022 AI and Trust in Healthcare Report" report has been added to ResearchAndMarkets.com's offering. The"AI and Trust in Healthcare"report examines...
Sepsis Diagnostics Market Worth $1,226.52 Million, Globally, by 2028 at 9.2% CAGR - Exclusive Report by The Insight Partners
13 mai 2022 09h32 HE
|
The Insight Partners
New York, May 13, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Sepsis Diagnostics Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product...
Persbericht Biocartis Group NV: SeptiCyte® RAPID krijgt 510(k) clearance van de US FDA
30 nov. 2021 11h40 HE
|
Biocartis NV
PERSBERICHT: 30 november 2021, 17:40 CET SeptiCyte® RAPID krijgt 510(k) clearance van de US FDA Mechelen, België, 30 november 2021 – Biocartis Group NV (de ‘Vennootschap’ of ‘Biocartis’), een...
Press release Biocartis Group NV: SeptiCyte® RAPID Receives 510(k) clearance by US FDA
30 nov. 2021 11h40 HE
|
Biocartis NV
PRESS RELEASE: 30 November 2021, 17:40 CET SeptiCyte® RAPID Receives 510(k) clearance by US FDA Mechelen, Belgium, 30 November 2021 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an...
Olaparib Reduces Organ Damage in Sepsis
13 sept. 2021 10h00 HE
|
Experimental Biology and Medicine
WASHINGTON, Sept. 13, 2021 (GLOBE NEWSWIRE) -- A recently published article in Experimental Biology and Medicine (Volume 246, Issue 17, September, 2021) examines the role of olaparib in sepsis. The...
BioAegis Awarded BARDA Contract to Advance Development of Gelsolin, a Novel Host-Directed Human Protein, for Patients with Sepsis and Severe Infection
29 juin 2021 13h58 HE
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases...
Jafron Biomedical Announces Global Advisory Board
21 juin 2021 07h00 HE
|
Jafron Biomedical Co.,Ltd.
ZHUHAI, China, June 21, 2021 (GLOBE NEWSWIRE) -- Jafron Biomedical, a pioneer in the blood purification industry, announced it's founding the Global Advisory Board, which includes the world’s top...